#United States #Durham #Biologics #Alcami Corporation

Alcami Corporation's Recent Acquisition: A Step Towards Enhanced Biologic Capabilities

In a significant move to augment its service offerings in the pharmaceutical arena, Alcami Corporation has made a strategic acquisition of a 37,000-square-foot facility situated at 4620 Creekstone Drive in Durham, North Carolina. This $6.7 million investment not only solidifies Alcami's foothold in the Research Triangle region but also boosts its laboratory services essential for advancing biologics.

Alcami is recognized as one of the leading U.S.-based contract development and manufacturing organizations (CDMO). The newly acquired facility is pivotal as it will function as a central hub for the company’s growing analytical and development capabilities. As part of its growth strategy, Alcami announced in October plans for a significant lab expansion at this facility, which is anticipated to be completed later this year. This expansion plays a crucial role in Alcami's ability to provide support for a wide array of sophisticated therapeutics. These include biologics, peptides, proteins, oligonucleotides, and even emerging drug modalities such as cell and gene therapies.

Katie Schlipp, President of Lab Operations at Alcami, remarked, "This acquisition marks another milestone in our strategy to deliver innovative, scalable solutions for our clients in the growing area of biologics. By expanding our analytical lab capabilities in RTP, we're able to support innovators in bringing life-changing therapies to patients faster and more reliably."

Strategically located in the hub of Research Triangle Park (RTP), the facility complements Alcami's established labs, sterile fill-finish manufacturing, and cGMP storage located in the same area. The strategic investments made by Alcami are poised to enhance its capacity to offer advanced solutions that optimize drug development processes while effectively addressing supply chain challenges.

In conjunction with the facility acquisition, Alcami has also recently qualified a third sterile fill-finish line at its RTP campus. This brings the total number of GMP-compliant lines for clinical and commercial production to five, reflecting the company’s commitment to enhancing its manufacturing capabilities.

These expansions highlight Alcami's dedication not merely to advancing drug development but also to ensuring reliable availability of life-saving therapies. As the demand for advanced biologics continues to rise, Alcami’s robust service offerings and infrastructure position the company as a key player in the pharmaceutical manufacturing landscape.

For more detailed insights into Alcami's expansive range of services, stakeholders and interested parties are encouraged to visit their official website at www.alcami.com.

About Alcami

Alcami Corporation has an extensive history spanning over 45 years, dedicated to facilitating the journey of pharmaceuticals and biologics from development to delivery. Headquartered in North Carolina, the organization prides itself on offering fully integrated lab services, drug product manufacturing, cGMP pharmaceutical storage, and broader support services. Alcami's private equity stakeholders include GHO Capital, The Vistria Group, and Ampersand Capital Partners, further solidifying its credibility and reach in the industry. With its continuous investment in capabilities and facilities, Alcami Corporation remains committed to redefining standards in drug development and manufacturing.